Primary Immuno-Deficiencies
Conditions
Brief summary
In order to accelerate the identification of genes responsibles of PID, and to improve the diagnosis of PID, the research team would like to validate a rapid and targeted method of high-throughput sequencing, on 301 genes, known to be involved in PID.
Detailed description
The Primary Immuno-Deficiencies (PID) are a set of rare diseases (estimated incidence of 1/5000). Today, more than 320 PID are described, and for 301 of them, the genetic cause has been identified, which underlines the huge diversity of all PID. The genetic diagnosis of PID is very important for the comprehension of PID physiopathology, their treatment and the genetic patient information. The characterisation of the clinical and immunological phenotype of patients allowed to identify a known morbid gene in 30% of cases, but for other patients, the genetic cause remains unknown, due to, inter alia, the lack of efficient tools for genetic exploration. In this context, each year, around 600 French and foreign patients are explored at the Necker hospital CEDI (Center for Immuno-Deficiencies Explorations), for whom are identified, in 30% of cases, a known genetic cause. Their treatment and the diagnosis of these patients is slow, partially because these studies are dependants of research fundings. In addition, in the current practice, the investigators sometimes discover incidental findings via the non-targeted high throughput genetic analyzes. The aim of the gene-panel is to improve the diagnosis procedures of these known diseases, by generalizing a rapid and targeted method of sequencing, on 301 genes, known to be involved in PID.
Interventions
BIOLOGICALBlood sampling
Additional blood sampling for the realization of the test on the gene panel
Sponsors
Assistance Publique - Hôpitaux de Paris
Imagine Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patient who need a genetic diagnosis of PID done at Necker's CEDI (Center for Immuno-Deficiencies Explorations), in the frame of an initial causal mutation identification * Patient having signed an informed consent form (or parents for minor patients) * Patient affiliated to National Health Care Insurance
Exclusion criteria
* Patient refusing to participate * Patient under legal guardianship * Patient that can't fulfill the study requirements, for any geographic, social or psychic reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the 2 sequencing methods | 2 years | Assess the efficacy of the identification of the genetic cause of PID, via the high throughput gene panel sequencing method, compared to the reference Sanger method, on patients with no identified mutation after analyzes done by available technics on hospital laboratories. |
Countries
France
Outcome results
None listed